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Abstract  Background: Anemia is the most frequent hematologic abnormality 
of HIV disease and one of the most common manifestations of nutritional 
deficiency disorders in the world. In sub-Saharan Africa, about 70% of the 
world’s people living with HIV/AIDS, where the prevalence of anemia is higher 
than in developed countries. The aim of this study was to determine the 
prevalence and factors associated with anemia among people living with HIV at 
Dodoma regional hospital during 2013-2014. Methodology: A retrospective 
cross-section study conducted among PLWHIV at Dodoma Regional Hospital 
between 2015 and 2016. A total of 869 PLWHIV were enrolled. Data extraction 
sheet were used to collect Socio- demographics, immune-hematological data and 
ARV status from existing patient’s files (CTC 2 card). Double entry of data in 
Microsoft excel were done and transferred for analyzing using SPSS v.16. 
Results: Majority of them were females 648(74.6%)and 508(58.2%) were 
between 19-45years with mean age of 38.84(±14.09). 824(94. 8%) were on 
ARV; where 640(73.6%) are from urban. The overall prevalence of anaemia 
among PLHIV was 59.5% of which 56.6% of these were on ARV, and 2.9% 
were not on ARV. Age, sex and CD4+ counts < 200cell/µl were among factors 
associated with anemia among PLWHIV. Conclusion: Moderate anaemia was 
common in the study population. Screening and management of anemia along 
with the proper use Anti-retroviral therapy may decrease risk of anemia and the 
effect ARV on red blood cells. Haemoglobin measurements should be taken 
before initiation of ARV and routinely followed among ARV users. 
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1. Introduction 
Anemia is a condition in which there is a decrease in the red blood cell count, hemoglobin and/or hematocrit values as 
compared to normal reference range for age, sex, race and altitude which decreases oxygen-carrying capacity of red blood 
cells to tissues [1]. Anemia was defined as a hemoglobin level of <12 g/dl for women and <13 g/dl for [1-5]. Also anemia 
was classified as mild (11–11.9 g/dl for women and 11– 12.9 g/dl for men), moderate (8–10.9 g/dl) and severe (<8 g/dl) 
[1]. Similarly this definition is in agreement with WHO (2006) classification of anemia(WHO 2006). 
Anemia is the most frequent hematologic abnormality of Human Immunodeficiency Virus (HIV) disease and one of the 
most common manifestations of nutritional deficiency disorders in the world. Among HIV-infected individuals from the 
United States and Europe, anemia has been independently associated with mortality, progression to Acquired Immune 
Deficiency Virus (AIDS), and decreased quality of life [6]. Although comparing rates of anemia among People Living with 
HIV (PLHIV) from different studies is complicated by variations in a number of factors including stage of HIV disease, 
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use of Antiretroviral Therapy (ART), and definition of anemia. Results from a review of the literature suggest that rates of 
anemia in PLHIV in a number of subpopulations tend to be higher in developing countries than in developed countries [7]. 
In sub-Saharan Africa, the prevalence of anemia among PLHIV are higher than in developed countries, and anemia is 
commonly caused by nutrient deficiencies, sickle cell disease, AIDS, malaria, hookworm infection, and other infections. 
Prevalence of anemia is generally higher in women than men [7]. The prevalence of anemia was higher in the HIV-positive 
cohort than in the HIV-negative cohort 28.1% and 15.1%, respectively [8]. In the study done by Brien and colleagues about 
70%–80% among those with HIV infection are anemic [6]. 
The symptoms of Anemia in HIV- infected patients are Fatigue, Diarrhea, nausea, or vomiting, Dizziness, headaches, 
Insomnia, Pain and nerve problems, skin rash, Injection site reactions, Dry mouth, Weight loss, Vivid dreams and 
infiltration of the bone marrow by neoplasm. This is caused by various factors such as Blood loss may be associated with 
such conditions as neoplastic disease (e.g., Kaposi sarcoma in the gastrointestinal tract) or gastrointestinal lesions that 
accompany opportunistic cytomegalovirus infection. Other than blood loss, the path physiology of HIV-associated anemia 
may involve 3 basic mechanisms: decreased RBC production, increased RBC destruction, and defective RBC production 
[9]. However HIV associated anemia is multifactorial and the principal factors are infection, use of myelosuppressive 
medications such as zidovudine, HIV infection itself ,a decreased production of endogenous erythropoietin, hemolytic 
anemia that may result from RBC autoantibodies, or may also develop as a consequence of the use of various medications 
[10]. Moreover anemia can result from thrombotic microangiopathy, disseminated intravascular coagulation, folic acid and 
vitamin B12 deficiencies, nutritional deficiencies such as vitamin and iron deficiencies are common in developing countries 
[11]. 
 Anemia can have severe consequences for PLHIV. Anemia can cause fatigue, shortness of breath, renal failure and 
increased heart rate, all of which substantially worsen a patient’s quality of life. Moreover, anemia can impact HIV disease 
progression, treatment options, and mortality. Several studies have indicated that among individuals with HIV, anemia is 
associated with HIV progression to AIDS. Furthermore, HIV patients with anemia are at a greater risk of mortality 
compared to their non-anemic counterparts, even after controlling for CD4+ cell count and viral load [6]. 
Based on previous studies done in United State of America did not show any association between zidovudine and 
anaemia among HIV patient but reported that patients who experienced anemia after initiating zidovudine were promptly 
switched to a different ART regimen [6]. However the study conducted in South America , the prevalence of anaemia was 
high in patients starting with non-AZT containing cART than patients initiating AZT-containing cART [12]. More 
interestingly is the study done in China by Shen et al, reported the prevalence of anaemia was high among newly diagnosed 
HIV infected patients on zidovudine based ART regimen [13]. 
Also a study done in Iran reported the prevalence of anaemia among HIV patients receiving no HAART were 39.7 %( 
1721) and receiving HAART were35.5 %( 7252) [14]. However the study from Eastern India, the prevalence of anaemia 
was 16.2% among patients receiving ART and the mean decline of haemoglobin was 6.3 ± 1.4 g/dl [15]. All these studies 
markedly showed significantly different findings. 
The study from Nigeria shows HIV infected patients on HAART had a significantly lower prevalence of anaemia 
compared with their HAART naive counterparts 51.15% and 69.17% respectively [16]. Furthermore, study conducted in 
south west Ethiopia shows the prevalence of anemia was high in HIV infected patients who are not under HAART [17]. 
Alem et al, from North west Ethiopia found that there was no statistically significant difference in prevalence of anemia 
between HAART users and non- users [3]. However another study conducted in the same country shows the prevalence of 
anaemia were 21.2% and 11.5% before HAART initiation and after HAART initiation respectively [1]. Moreover the study 
conducted from rural Tanzania reported that, HIV infected patients after receiving ART hemoglobin level were increased 
[18]. 
In 2014 in the United State of America and China, reported that CD4+ cell count of less than 200 cells/mL are associated 
with an increased prevalence of anemia ,but according to their studies it was found that, no any an association between 
ART regimen and anemia , where the prevalence of anemia among female was high as compared to males with the age 
ranging between 20-34years [5,6,12,13]. 
No significant association was reported when looking at anaemia and lower CD4+ cells count as well as zidovudine use 
[14], however, Agarwal and his colleagues reported that, there were no significant association between CD4+ cell count 
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with anemia, but antiretroviral medication was associated with risk of developing anaemia among females than males 
[15,19]. 
Anemia was reported to be a common manifestation in the Mexican population without antiretroviral therapy, in HIV 
naïve patients, a CD4+ Cell Count <200 cells/mm3 was associated with an increased risk of anemia [10]. Significant and 
positive correlation was found between anaemia and lower CD4+ cell count [20].The prevalence of anaemia was highest 
among patients who had a CD4 lymphocyte count of 100–199 cells/μL, the increase in prevalence of anaemia with 
decreased CD4+ cell count was statistically significant and 62% of females were anemic [4]. Similarly, the study from 
North west Ethiopia reported CD4+ cell count was not statistically significant association with risk of anemia [3,18]. 
Thus, anaemia is the most problems of HIV disease and one of the most common manifestations of nutritional deficiency 
disorders in the world [7]. Anemia can have severe consequences for PLHIV that can cause life threatened conditions like 
HIV disease progression, treatment options, and mortality. The effort done previously was to treat anaemia with EPO or a 
blood transfusion with ZDV [21]. Other effort was to treat patients with HAART which does not contain Zidovudine. 
Therefore, anemia is a major problem among HIV patients. There is a need updating data on anaemia prevalence in 
people living with HIV patients in each region since it helps in reflecting the magnitude of the problem. Therefore, this 
study is intended to assess the prevalence and factors associated with anaemia among People living with HIV at Dodoma 
referral hospital as there is no evidence based study conducted based on prevalence of anemia among PLWHIV. 
2. Materials and Method 
2.1. Study design and study population  
A retrospective cross-sectional study which included data from records/files to patients who attended the clinic from 
2015-2016. This study was conducted at Dodoma Regional Hospital during the month of March and April 2015 and 
included all HIV-infected patients who visited CTC at Dodoma regional hospital from 2015-2016. 
2.2. Data collection methods 
Data were collected using information available in the patients file from CTC department at Dodoma Regional Hospital. 
These files are kept at CTC department special medical records room and securely maintained. From these files data were 
extracted by accessing each file one by one, were all HIV infected patients (male and female) attended CTC were included; 
excluding only Pregnant women with HIV infection since pregnant was thought to confound the results. 
2.3. Ethical consideration 
This study was conducted under the permission of Dean of Faculty of Medicine of Kilimanjaro Christian Medical 
University college, Research Course coordinator and the permission obtained from the Medical Officer in charge of 
Dodoma Regional Hospital, by considering that the anonymity and confidentiality was observed. 
2.4. Data handling and analysis 
Data were coded and double entry of data were done using Microsoft excel and analyzed using the Statistical Package 
for Social Science (SPSS) version 16. Descriptive statistics was used to summarize data, where; in continuous data, mean 
with standard deviation (SD) was used to describe the spread of data around the mean, frequencies and percentages was 
used in categorical variables. Also Chi-square test was used to analyze categorical data and variables were compared. The 
crude (unadjusted) and multivariate (adjusted) logistic regression analysis of factors associated with anaemia among PLHIV 
were examined. A p-value <0.05 at 95%CI was considered statistically significant. 
3. Results 
3.1. General characteristics of the study patients 
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A total of 869 people living with HIV were collected from CTC files. Majority of them were females 648(74.6%). Almost 
508(58.2%) were found to be in age group between 19-45. Where the mean age (±SD) of participants at enrollment was 
38.84(±14.09). Majority of them were ARV users 824(94.8%). Most of them were Christian 479(55.1%) followed by 
Islamic 318(36.6%). Where majority was from urban 640 (73.6%) (Table 1). 
Table 1. Characteristics of the study participants (N=869) 

























































3.2. Prevalence of anaemia among people living with HIV 
A total of 869 PLHIV were enrolled in the study. The overall prevalence of anemia was 517(59.9%), (Figure 1). Also in 
this study moderate anaemia were found to be higher 313(36%) followed by mild anaemia 110(12.7%), (Figure 2).  
 
Figure 1. Overall prevalence of anaemia among PLHIV 
40.5% 
59.5% 
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Figure 2. Severity of anaemia classification among PLHIV 
3.3. Prevalence of anaemia among PLHIV by ARV status 
A total of 869 PLHIV were enrolled in the study with their ARV status. The overall prevalence on patients not on ARV 
were2.9%, where, 0.8% were found with severe anaemia.1.4% was found with moderate anaemia and 0.7% was found with 
mild anaemia. Moreover, patients who were on ARV the overall prevalence were 56.6%, where 10.0% were found with 
severe anaemia, 34.6% with moderate anaemia and 12.0% were found with mild anaemia (Table 2). 
Table 2. Prevalence of anaemia among PLHIV by ARV status n=517 
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On ARV 87(10.0) 301(34.6) 104(12.0) 492(56.6) 
3.4. Factors associated with anaemia among PLHIV  
In Univariate analysis sex, age ≤30 and CD4+ counts <200cell/ µl were statistically associated to anaemia. Therefore, 
being females is as having 55% chance of being anemic as compared to males (OR 0.58 (0.42-0.80) P= 0.001). The odds 
being anemic among people with CD4 counts <200cell/ µ is 55% compared to other above this range. The odds of anaemia 
among age 46+ years old is 47 %( OR 0.53, 95%CI=0.73-0.76) though statistically not significant (Table 3).  
In Multivariate logistic regression analysis, it is still reported that, Females, CD4 counts of <200cell/ul and age of 
<30years are among factors associated with anemia among ARV users (Table 4). 
4. Discussion 
Anaemia among PLHIV patients is among the problem that faces these patients; and it is much more serious to those on 
ARV compared to those not on ARV; despite the fact that ARV is needed to support the life of the people living with HIV. 
This study was mainly conducted to the assessment of the prevalence and factors associated with anemia among people 
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patients and also to assess whether or not ARV, age, sex and CD4+ cells count has any association to the anemic patients 
with HIV. 
Table 3. Univariate logistic regression analysis associated of anaemia among PLHIV. N=869 
Table 4. Multivariate logistic regression analysis of factors associated with anaemia among PLHIV. N=869 
           Adjusted  











































This study shows the overall prevalence of anaemia among PLHIV was 59.5%, where 2.9% patients were not on ARV, 
however, the overall prevalence of anaemia on patients who were on ARV was 56.6%, of them 10.0% were found with 
severe anaemia,34.6% with moderate anaemia and 12.0% were found with mild anaemia. This is contrally to the study 
conducted at Northwest Ethiopia, where the prevalence of anemia was high to the patients on ARV 86%, of them, 1.6%, 
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14.8%, 53.6% had severe, moderate and mild anemia respectively [3].On other hand lower prevalence of anaemia was 
reported in Uganda 16% , 0.4% had severe anemia , 6.2% had moderate anemia and 9.4% had mild anemia [22], but slightly 
higher from Northern Tanzania 40% [18]. Differences in findings might have been attributed by time frame (duration) of 
the study, sample size, geographical area, study population and study design as well as ethnicity as all these factor can 
contribute to differences in findings. 
After multivariate logistic regression analysis, it was demonstrated that, levels of CD4 + T cell <200cell/µl, was not 
statistical significant associated with anemia with marginal p-value. This was in the same line with the report from Eastern 
India and Northwest Ethiopia where they did not find any significant association with CD4+ T cells count with anaemia 
[3,15,19]. However other studies reported the statistical significance of CD4+Tcell <200cell/µl to be associated with 
anaemia in USA [21], China [13], Hispanic [5], Iran [14], Ghana [20], Uganda [22]. Differences in finding might be due to 
healthcare policies, HIV subtype and antiretroviral regimen types that could have contributed for the differences in findings 
between developed countries and resource- limited settings. 
 Age among females with ≤30years was a positive predictor of anaemia among PLWHIV, which is in agreement with 
findings from Iran [14], Northwest Ethiopia [3,4], Uganda [22], Tanzania [18] and USA but there were observed slightly 
differences in age group of 31-45 [21], Similarly to the study from Northwest Ethiopia which reported that sex and age 
were not associated with anemia [1]. Menstrual blood loss and multiple deliveries was among the reasons given in due 
course of the difference in findings. 
This study reported also that, patients on ARV were associated with anemia. This is in agreement with studies from USA 
[6], Northwest Ethiopia [3], rural Tanzania [18], but different to other studies done in India, where ARV was significant 
associated with anaemia [15]. However the study from Nigeria reported patients who on ARV have significantly higher 
prevalence of anaemia than those not on ARV [16]. These differences are attributed by HIV sero-prevalence and ethnicity. 
In conclusion, anemia was prevalent in PLWHIV patients. The prevalence of anemia was higher in patients who were 
on ARVs than those who were not on ARVs. However, females on ARV were much more prevalent in anemia than not on 
ARV. HIV sero-prevalence, ethnicity and geographical location are said to contribute to the difference in findings. 
Therefore, early screening, diagnosis and management of anaemia is essential in PLWHIV for proper health recovery and 
monitoring. 
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